A powerful enabling system that highlights the most viable embryos to conceive in IVF induced pregnancy. This technology is based on the principle of thermochemiluminescence (TCL)andutilises oxidative stress as a biomarker for the quantitative assessment of the reproductive potential of embryos. Thissystemically increases the probability of IVF pregnancy against an existing landscape needing multiple IVF cycles to successfully conceive.Clinically trialled in 2 separate studies on a total of 276 embryos, this technology has proven to have at least 20% success rate increase in pregnancy. Its non-invasive, inexpensive, simple, and fast assesment aspects would streamline and ramp up pregnancy rates in current IVF facilites.
The system utilises a novel biomarker of oxidative qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasiveand accurate manner. It will meet this need by providing a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of the culture media in which the embryo is incubated. The Analyzer's technology and TCL method are disruptive technologies encompassed within the system measuring these oxidation state levels. As a result, the solutionwill increase IVF pregnancy outcomes by an unprecedented 20% and beyond. The successful identificationof a single fertile embryo would remove all costs associated with multiple embryo transfers. It will also remove all health fall-outs to mother and infant that come with multiple gestation in current IVF pregnancy.
The primary application area is embryo selection in IVF process. However, the technology is a platform that enables more applications. Oxidative stress (OS) could be used asa biomarker for: Cardiological applications (i.e. heart failure) Diagnosis of neurodegenerative diseases(Alzheimer’s, Parkinson, ALS, Huntington) Diagnosis and monitoring of treatment for Age Related Macular Degeneration (AMD) Early detection of Preeclampsia Diagnosis of Mild Traumatic Brain Injury(MTBI)
1. Benefit to IVF fertility clinics and reproductive endocrinologist: (a) Unparalleled efficacy.This technology will increase successful pregnancy through IVF procedures by at least 25% – an unprecedented figure not seen in any other solution form. This will improve overall statistics of the clinic for marketing purposes, and reduce excessive financial, manpower, as well as equipment resources used for today’s methods (e.g. MET’s and Multiple cycles) in order to improve pregnancy rates. (b) Ease of Use.This technology is straightforward for any IVF specialist/reproductive endocrinologist in an IVF facility to carry forth. Embryos are left untouched, where only its culture media is examined. This can be accessed by ordinary pipettes, taking a 15 uL sample from the spent media, to be placed in a petri dish for analysis. No training is required. This technologywill quantitatively record propensity for pregnancy for each, listed in descending order. The most viable embryos would then undergo standard embryonic transfer. 2) Benefit to mothers and infants: Removal of health risks.This technology prevents a multiple gestation scenario that faces a 16 times probability increase with current IVF procedures due to the METs required for higher success rates.In this regard, this technology acts as an enabler to vastly reduce associated health fall out risks for mothers (decrease rate of 20% for hypertension, 30% pre-eclampsia, 12% gestational diabetes, and probability decrease of 20 times for miscarriage, haemorrhage, anaemia, and fatality). This also reduces associated health fall outs for the birthed infant (rate decrease by 50% for premature births and a 6 times probability decrease for premature death, pneumonia, meningitis, premature retinopathy, and hearing loss). Hence, this technology provides for safer procedural outcomes on a common parenthood planning practice 3) Benefit to the state and families: Reduced cost.This technology is expected to reduce the overall costs associated with current IVF procedure due to a clinically efficient embryo identification process with the Analyzer technology whichpicks only the best embryos likely to conceive. This ultimately reduces the number of complete cycles, where the bottle neck lies in embryonic transfers that end up not conceiving. This number is currently kept at up to 4 embryonic transfers due to the delicate survivability of embryos, of which a complete new cycle is undertaken to ready new emrbyos. Hence, the common practice isto improve the odds of conception, but thisresults in multiple gestations as mentioned above. This technology is able to contain IVF treatment to a singular cycle, removing the multiple cycles consisting of: stimulation of multiple follicles and eggs; retrieval of eggs; fertilisation in dish; and embryonic transfer. This is key tocost reductions, where sky-rocketing cost ofprocedures are attributed to multiple cycles.